June 9th, 2020:
VALLEY FORGE, Pa., June 9, 2020 /PRNewswire/ -- L.E.A.F. Pharmaceuticals LLC ("LEAF"), a global pharmaceutical company focused on developing novel anticancer drugs, announced today that results from a preclinical study of LEAF-1401, the Company's lead anticancer product, were presented at the 2020 Virtual Annual Meeting of ASCO held from May 29 - 31, 2020.
July 11th, 2019:
KIGALI, Rwanda and VALLEY FORGE, Pennsylvania, July 11, 2019/PRNewswire/ -- L.E.A.F. Rwanda Ltd ("LEAF Rwanda") announced today that it has signed a manufacturing agreement with a US Contract Manufacturing Organization (CMO), through its United States (US) parent company, L.E.A.F. Pharmaceuticals LLC, to manufacture its first complex generic anticancer medicine, LEAF-1404, under global current good manufacturing practices (cGMP).
October 29th, 2018:
VALLEY FORGE, Pa., Oct. 29, 2018 /PRNewswire/ -- L.E.A.F. Pharmaceuticals LLC ("LEAF"), a global pharmaceutical company focused on developing novel anticancer drugs, today announced that it has received positive feedback following Pre-Investigational New Drug (Pre-IND) interactions with the United States Food and Drug Administration (US FDA) for four of its lead anticancer products, LEAF-1401, LEAF-1701, LEAF-1702 and LEAF-1703. These products are new generation onco-immuno antimetabolites that are designed to disrupt dysregulated serine-glycine 1-carbon metabolism in cancer and the immune system.
August 16th, 2017:
VALLEY FORGE, Pa., Aug. 16, 2017 /PRNewswire/ -- L.E.A.F. Pharmaceuticals LLC, a global pharmaceutical company located in the historic area of Valley Forge, Pennsylvania, USA, with a mission to discover, develop and commercialize innovative and safe therapies for cancer, today announced the establishment of L.E.A.F. Rwanda Ltd. (L.E.A.F. Rwanda), a biotechnology company, headquartered in Kigali, Rwanda.
March 1st, 2017:
L.E.A.F. Pharmaceuticals raises over forty million US dollars from private and institutional investors. This will enable L.E.A.F. to advance its lead anticancer drug candidates to the investigational new drug (IND) application phase and worldwide regulatory registration directed clinical development. A portion of the funds will also be used to manufacture and make available, among others, a key anticancer drug currently inaccessible to patients suffering from cancer in many parts of the world.
October 20th, 2016:
Dr. Clet Niyikiza Receives a 2016 Health Care Innovator Award at the Awards Ceremony held at the Pennsylvania Convention Center. (Photo provided by The Philadelphia Business Journal; photo credit - Paul Coker)
October 19th, 2016:
Press Release Issued: 2016 Health Care Innovator Award Announcement
September 22nd, 2016:
Dr. Clet Niyikiza and L.E.A.F. Pharmaceuticals are among the recipients of the 2016 Health Care Innovator Awards.
For more details, please visit the event webpage.
These awards are “honoring the people and companies who are disrupting the health care and biotechnology industries and solidifying Greater Philadelphia’s reputation as a center for innovation.”
This award follows the recent recognition of Dr. Niyikiza by Princeton University for his scientific achievements in the discovery and development of ALIMTA®, an anticancer drug used world-wide to treat lung cancer and the asbestos-related cancer, mesothelioma.
August 11th, 2016:
May 1st, 2016:
L.E.A.F. Pharmaceuticals is pleased to appoint Dr. Victor Moyo as Senior Vice President, Chief Medical Officer, and Head of Research and Development.
March 13th, 2016:
L.E.A.F. Pharmaceuticals makes a donation to the Imbuto Foundation in support of the Foundation’s 15-year anniversary program activities, which support the development of a healthy, educated and prosperous society in Rwanda. For details on how to contribute to the Imbuto Foundation, please visit the Imbuto Foundation website.
February 18th, 2016:
L.E.A.F. Pharmaceuticals announces the international publication of its initial utility patent under the Patent Cooperation Treaty of Paris, France (PCT) by the World Intellectual Property Organization (WIPO).
January 1, 2016:
L.E.A.F. Pharmaceuticals raises additional funds of over $2 Million from a private equity fund, to advance its pipeline products and prepare for Investigational New Drug (IND) applications.
October 1st, 2015:
L.E.A.F. Pharmaceuticals welcomes Alain-Christian Niyikiza as Research Project Management Associate.
December 1, 2014:
L.E.A.F. Pharmaceuticals goes live on the Internet and launches www.leafpharmaceuticals.com.
October 27, 2014:
L.E.A.F. Pharmaceuticals welcomes new team member, Raffaella Lo Castro, as Head of Communications and Investor Relations.
L.E.A.F. Pharmaceuticals initiates the development of its first two prototype drugs against cancer.
September 5, 2014:
Dr. Clet Niyikiza is recognized along with four of his former colleagues at Eli Lilly and Company by Princeton University, for their significant scientific achievements in the development of the anticancer drug, Alimta®. Princeton University erected a plaque honoring the five researchers on the main lobby entrance wall of the new state-of-the art Princeton University Chemistry Building in Princeton, New Jersey, USA.
August 15, 2014:
L.E.A.F. Pharmaceuticals raises over $1 Million from a private equity fund, to design its first four pipeline products.
August 14, 2014:
L.E.A.F. Pharmaceuticals LLC is registered to conduct business in Pennsylvania in addition to Delaware.
L.E.A.F. Pharmaceuticals opens its doors for business with initial funding to develop its lead prototypes.
June 30, 2014:
L.E.A.F. Pharmaceuticals LLC is registered in Delaware.